Skip to main content

Table 2 Summary of results

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

 

Ceftolozane/tazobactam

Piperacillin/tazobactam

Incremental

Ceftolozane/tazobactam - Piperacillin/tazobactam

Total costs per patient (USD 2015)

$36,413

$36,028

$385

Total QALYs (undiscounted) per patient

11.82

11.74

0.08

Total QALYs (discounted) per patient

9.19

9.13

0.06

Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained)

  

$6128

Hospitalization days saved per patient

  

0.25

  1. QALY Quality-adjusted life year